Skip to main content

Table 3 Results of multivariate analysis showing the significant prognostic factors for different survival outcomes in nasopharyngeal carcinoma patients

From: Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma

FactorHazard ratio95% CIP
Overall survival
 Chemotherapy (IMRT vs. IMRT/CT)1.1520.346–3.8340.818
 Age (≤45 years vs. > 45 years)1.3070.347–4.9300.692
 Sex (male vs. female)0.9090.239–3.4650.889
 TNM stage (II vs. III [T3N0M0])5.7971.768–19.0070.004
Disease-free survival
 Chemotherapy (IMRT vs. IMRT/CT)0.8400.303–2.3280.738
 Age (≤45 years vs. > 45 years)1.0490.351–3.1350.932
 Sex (male vs. female)0.5900.166–2.0920.414
 TNM stage (II vs. III [T3N0M0])4.9901.772–14.0470.002
Locoregional relapse-free survival
 Chemotherapy (IMRT vs. IMRT/CT)1.4760.242–9.0110.673
 Age (≤45 years vs. > 45 years)0.8320.136–5.0800.842
 Sex (male vs. female)1.0150.212–3.4570.973
 TNM stage (II vs. III [T3N0M0])1.5750.176–14.0990.685
Distant metastasis-free survival
 Chemotherapy (IMRT vs. IMRT/CT)0.9050.259–3.1550.875
 Age (≤45 years vs. > 45 years)1.0750.270–4.2710.919
 Sex (male vs. female)0.9500.241–3.7360.941
 TNM stage (II vs. III [T3N0M0])4.7051.322–16.7510.017
  1. IMRT Intensity-modulated radiotherapy, CI Confidence interval, CT Chemotherapy